A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)
A phase 2 trial of Toripalimab, Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Lyvgen Biopharma Holdings Limited, active and no longer recruiting.
Overview
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) is a phase 2 interventional study registered as NCT06378177 by Lyvgen Biopharma Holdings Limited, with 64 participants planned, started 2024-06-21 and due to reach its primary completion in 2027-10-31. Interventions recorded: LVGN6051 Monoclonal Antibody Injection, toripalimab Injection, Paclitaxel injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialStudy to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- CompanyCoherus BioSciences
- TrialJUPITER-06
Shares Toripalimab, Paclitaxel / nab-paclitaxel.
- TrialA Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.
- TrialJUPITER-02
- PersonLi Zhang
- TrialStudy of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst
Shares Paclitaxel / nab-paclitaxel, Head and neck squamous cell carcinoma.